$17.00
0.98%
Nasdaq, May 27, 08:48 pm CET
ISIN
US07373V1052
Symbol
BEAM
Sector
Industry

Beam Therapeutics Inc Stock price

$16.83
-3.04 15.30% 1M
-9.82 36.85% 6M
-7.97 32.14% YTD
-7.18 29.90% 1Y
-18.16 51.90% 3Y
-8.79 34.31% 5Y
-1.92 10.24% 10Y
Nasdaq, Closing price Fri, May 23 2025
-0.41 2.38%
ISIN
US07373V1052
Symbol
BEAM
Sector
Industry

Key metrics

Market capitalization $1.69b
Enterprise Value $841.64m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 13.25
P/S ratio (TTM) P/S ratio 26.64
P/B ratio (TTM) P/B ratio 1.92
Revenue growth (TTM) Revenue growth -83.18%
Revenue (TTM) Revenue $63.52m
EBIT (operating result TTM) EBIT $-415.57m
Free Cash Flow (TTM) Free Cash Flow $-356.19m
Cash position $850.74m
EPS (TTM) EPS $-4.54
P/E forward negative
P/S forward 31.60
EV/Sales forward 15.71
Short interest 21.54%
Show more

Is Beam Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Beam Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Beam Therapeutics Inc forecast:

15x Buy
83%
3x Hold
17%

Analyst Opinions

18 Analysts have issued a Beam Therapeutics Inc forecast:

Buy
83%
Hold
17%

Financial data from Beam Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
64 64
83% 83%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 112 112
5% 5%
176%
- Research and Development Expense 368 368
16% 16%
579%
-394 -394
152% 152%
-620%
- Depreciation and Amortization 22 22
10% 10%
35%
EBIT (Operating Income) EBIT -416 -416
135% 135%
-654%
Net Profit -377 -377
184% 184%
-593%

In millions USD.

Don't miss a Thing! We will send you all news about Beam Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Beam Therapeutics Inc Stock News

Neutral
GlobeNewsWire
13 days ago
Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101
Neutral
GlobeNewsWire
14 days ago
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 11:00 a.m.
Neutral
GlobeNewsWire
15 days ago
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of ...
More Beam Therapeutics Inc News

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.

Head office United States
CEO John Evans
Employees 483
Founded 2017
Website beamtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today